315 related articles for article (PubMed ID: 27572810)
1. MRI-CEST assessment of tumour perfusion using X-ray iodinated agents: comparison with a conventional Gd-based agent.
Anemone A; Consolino L; Longo DL
Eur Radiol; 2017 May; 27(5):2170-2179. PubMed ID: 27572810
[TBL] [Abstract][Full Text] [Related]
2. In Vitro and In Vivo Assessment of Nonionic Iodinated Radiographic Molecules as Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Tumor Perfusion Agents.
Longo DL; Michelotti F; Consolino L; Bardini P; Digilio G; Xiao G; Sun PZ; Aime S
Invest Radiol; 2016 Mar; 51(3):155-62. PubMed ID: 26460826
[TBL] [Abstract][Full Text] [Related]
3. The interaction between iodinated X-ray contrast agents and macrocyclic GBCAs provides a signal enhancement in T
Di Gregorio E; Arena F; Gianolio E; Ferrauto G; Aime S
Magn Reson Med; 2022 Jul; 88(1):357-364. PubMed ID: 35253921
[TBL] [Abstract][Full Text] [Related]
4. Dual assessment of kidney perfusion and pH by exploiting a dynamic CEST-MRI approach in an acute kidney ischemia-reperfusion injury murine model.
Irrera P; Consolino L; Cutrin JC; Zöllner FG; Longo DL
NMR Biomed; 2020 Jun; 33(6):e4287. PubMed ID: 32153058
[TBL] [Abstract][Full Text] [Related]
5. Investigating plasma volume expanders as novel macromolecular MRI-CEST contrast agents for tumor contrast-enhanced imaging.
Consolino L; Irrera P; Romdhane F; Anemone A; Longo DL
Magn Reson Med; 2021 Aug; 86(2):995-1007. PubMed ID: 33764575
[TBL] [Abstract][Full Text] [Related]
6. A comparison of iopromide and iopamidol, two acidoCEST MRI contrast media that measure tumor extracellular pH.
Moon BF; Jones KM; Chen LQ; Liu P; Randtke EA; Howison CM; Pagel MD
Contrast Media Mol Imaging; 2015; 10(6):446-55. PubMed ID: 26108564
[TBL] [Abstract][Full Text] [Related]
7. Assessment of cerebral perfusion by first-pass, dynamic, contrast-enhanced, steady-state free-precession MR imaging: an animal study.
Runge VM; Kirsch JE; Wells JW; Woolfolk CE
AJR Am J Roentgenol; 1993 Mar; 160(3):593-600. PubMed ID: 8430562
[TBL] [Abstract][Full Text] [Related]
8. MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients.
Kuhn MJ; Hammer GM; Swenson LC; Youssef HT; Gleason TJ
Comput Med Imaging Graph; 1994; 18(5):391-9. PubMed ID: 7954317
[TBL] [Abstract][Full Text] [Related]
9. Using two chemical exchange saturation transfer magnetic resonance imaging contrast agents for molecular imaging studies.
Ali MM; Liu G; Shah T; Flask CA; Pagel MD
Acc Chem Res; 2009 Jul; 42(7):915-24. PubMed ID: 19514717
[TBL] [Abstract][Full Text] [Related]
10. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging.
Hamilton BE; Nesbit GM; Dosa E; Gahramanov S; Rooney B; Nesbit EG; Raines J; Neuwelt EA
AJR Am J Roentgenol; 2011 Oct; 197(4):981-8. PubMed ID: 21940589
[TBL] [Abstract][Full Text] [Related]
12. Flip-angle based ratiometric approach for pulsed CEST-MRI pH imaging.
Arena F; Irrera P; Consolino L; Colombo Serra S; Zaiss M; Longo DL
J Magn Reson; 2018 Feb; 287():1-9. PubMed ID: 29272735
[TBL] [Abstract][Full Text] [Related]
13. Measuring in vivo tumor pHe with CEST-FISP MRI.
Sheth VR; Li Y; Chen LQ; Howison CM; Flask CA; Pagel MD
Magn Reson Med; 2012 Mar; 67(3):760-8. PubMed ID: 22028287
[TBL] [Abstract][Full Text] [Related]
14. Effect of tamoxifen in an experimental model of breast tumor studied by dynamic contrast-enhanced magnetic resonance imaging and different contrast agents.
Marzola P; Ramponi S; Nicolato E; Lovati E; Sandri M; Calderan L; Crescimanno C; Merigo F; Sbarbati A; Grotti A; Vultaggio S; Cavagna F; Lorusso V; Osculati F
Invest Radiol; 2005 Jul; 40(7):421-9. PubMed ID: 15973133
[TBL] [Abstract][Full Text] [Related]
15. A new contrast in MR mammography by means of chemical exchange saturation transfer (CEST) imaging at 3 Tesla: preliminary results.
Schmitt B; Zamecnik P; Zaiss M; Rerich E; Schuster L; Bachert P; Schlemmer HP
Rofo; 2011 Nov; 183(11):1030-6. PubMed ID: 22034086
[TBL] [Abstract][Full Text] [Related]
16. Dynamic gadoteridol-enhanced MR imaging in the end of growing long bone of piglets.
Li XM; Xiong W; Hu DY; Yu C; Peng WJ; Hu JW; Feng DY; Hu XM; Li HL; Qiu L; Li F
Chin Med J (Engl); 2008 Oct; 121(19):1932-8. PubMed ID: 19080127
[TBL] [Abstract][Full Text] [Related]
17. Consecutive acquisition of time-resolved contrast-enhanced MR angiography and perfusion MR imaging with added dose of gadolinium-based contrast agent aids diagnosis of suspected brain metastasis.
Tsuchiya K; Aoki S; Shimoji K; Mori H; Kunimatsu A
Magn Reson Med Sci; 2013; 12(2):87-93. PubMed ID: 23666159
[TBL] [Abstract][Full Text] [Related]
18. Quantitative comparison of delayed ferumoxytol T
Horváth A; Varallyay CG; Schwartz D; Toth GB; Netto JP; Barajas R; Várallyay P; Szidonya L; Firkins J; Youngers E; Fu R; Ambady P; Bogner P; Neuwelt EA
Magn Reson Med; 2018 Jul; 80(1):224-230. PubMed ID: 29205477
[TBL] [Abstract][Full Text] [Related]
19. Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read.
Koenig M; Schulte-Altedorneburg G; Piontek M; Hentsch A; Spangenberg P; Schwenke C; Harders A; Heuser L
Eur Radiol; 2013 Dec; 23(12):3287-95. PubMed ID: 23824152
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol.
Dósa E; Guillaume DJ; Haluska M; Lacy CA; Hamilton BE; Njus JM; Rooney WD; Kraemer DF; Muldoon LL; Neuwelt EA
Neuro Oncol; 2011 Feb; 13(2):251-60. PubMed ID: 21163809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
